<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Conferences 2016</title>
  <meta content="text/html; charset=UTF-8" http-equiv="Content-Type">
  <meta name="description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here.">
  <meta name="generator" content="bookdown 0.1 and GitBook 2.6.7">

  <meta property="og:title" content="Conferences 2016" />
  <meta property="og:type" content="book" />
  <meta property="og:url" content="http://shanmdphd.github.io/Conferences/" />
  <meta property="og:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />
  <meta property="og:description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here." />
  <meta name="github-repo" content="shanmdphd/shanmdphd.github.io" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Conferences 2016" />
  
  <meta name="twitter:description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here." />
  <meta name="twitter:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />

<meta name="author" content="Sungpil Han">

<meta name="date" content="2016-10-14">

<script type="text/x-mathjax-config">
MathJax.Hub.Config({
  TeX: { equationNumbers: { autoNumber: "AMS" } }
});
</script>

  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="-fda-.html">
<link rel="next" href="translation-and-convergence-for-future-medicine.html">

<script src="libs/jquery/jquery.min.js"></script>
<link href="libs/gitbook/css/style.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-fontsettings.css" rel="stylesheet" />










<link rel="stylesheet" href="css/style.css" type="text/css" />
</head>

<body>


  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">Conferences</a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> Introduction</a></li>
<li class="chapter" data-level="2" data-path="section-2.html"><a href="section-2.html"><i class="fa fa-check"></i><b>2</b> 심장내과</a></li>
<li class="chapter" data-level="3" data-path="-3.html"><a href="-3.html"><i class="fa fa-check"></i><b>3</b> 심장내과 3부</a></li>
<li class="chapter" data-level="4" data-path="cancer-immunotherapy.html"><a href="cancer-immunotherapy.html"><i class="fa fa-check"></i><b>4</b> Cancer immunotherapy</a></li>
<li class="chapter" data-level="5" data-path="bioimaging-2016-04-29.html"><a href="bioimaging-2016-04-29.html"><i class="fa fa-check"></i><b>5</b> Bioimaging 2016-04-29</a></li>
<li class="chapter" data-level="6" data-path="-fda-.html"><a href="-fda-.html"><i class="fa fa-check"></i><b>6</b> 신약개발을 위한 FDA의 바이오이미징 표준화 프로그램 |</a><ul>
<li class="chapter" data-level="6.1" data-path="-fda-.html"><a href="-fda-.html#-center-for-bioimaging-of-new-drug-development-amc"><i class="fa fa-check"></i><b>6.1</b> 김정곤 Center for Bioimaging of New Drug Development AMC</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="kscpt.html"><a href="kscpt.html"><i class="fa fa-check"></i><b>7</b> 2016 KSCPT</a><ul>
<li class="chapter" data-level="7.1" data-path="kscpt.html"><a href="kscpt.html#opening-remark"><i class="fa fa-check"></i><b>7.1</b> Opening Remark</a></li>
<li class="chapter" data-level="7.2" data-path="kscpt.html"><a href="kscpt.html#first-session"><i class="fa fa-check"></i><b>7.2</b> First Session</a><ul>
<li class="chapter" data-level="7.2.1" data-path="kscpt.html"><a href="kscpt.html#precision-medicine-a-clinical-pharmacological-perspective"><i class="fa fa-check"></i><b>7.2.1</b> 13:20~14:00 Precision Medicine: A Clinical Pharmacological Perspective</a></li>
<li class="chapter" data-level="7.2.2" data-path="kscpt.html"><a href="kscpt.html#the-role-of-pharmacogenomics-in-drug-development-regulatory-review-and-clinical-practice"><i class="fa fa-check"></i><b>7.2.2</b> 14:00~14:30 The role of pharmacogenomics in drug development, regulatory review and clinical practice</a></li>
<li class="chapter" data-level="7.2.3" data-path="kscpt.html"><a href="kscpt.html#the-liver-gut-microbiota-axis-modulates-inter-individual-variability-in-xenobiotic-disposition-and-toxicology"><i class="fa fa-check"></i><b>7.2.3</b> 14:30~15:00 The Liver-Gut Microbiota Axis Modulates Inter-Individual Variability in Xenobiotic Disposition and Toxicology</a></li>
</ul></li>
<li class="chapter" data-level="7.3" data-path="kscpt.html"><a href="kscpt.html#second-session"><i class="fa fa-check"></i><b>7.3</b> Second Session</a><ul>
<li class="chapter" data-level="7.3.1" data-path="kscpt.html"><a href="kscpt.html#the-role-of-stem-cells-in-discovery-and-validation-of-pharmacogenomic-markers"><i class="fa fa-check"></i><b>7.3.1</b> 15:20~15:50 The role of stem cells in discovery and validation of pharmacogenomic markers</a></li>
<li class="chapter" data-level="7.3.2" data-path="kscpt.html"><a href="kscpt.html#pharmacogenomics-and-epigenomics"><i class="fa fa-check"></i><b>7.3.2</b> 15:50~16:20 Pharmacogenomics and Epigenomics</a></li>
<li class="chapter" data-level="7.3.3" data-path="kscpt.html"><a href="kscpt.html#emerging-roles-of-human-cyp1b1-in-cancer-growth-and-metastasis"><i class="fa fa-check"></i><b>7.3.3</b> 16:20~16:50 Emerging roles of human CYP1B1 in cancer growth and metastasis</a></li>
<li class="chapter" data-level="7.3.4" data-path="kscpt.html"><a href="kscpt.html#omics-for-precision-medicine-clinical-implementation-in-oncology"><i class="fa fa-check"></i><b>7.3.4</b> 16:50~17:20 omics for precision Medicine : Clinical Implementation in oncology</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="8" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html"><i class="fa fa-check"></i><b>8</b> “Translation and Convergence for Future Medicine”</a><ul>
<li class="chapter" data-level="8.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#plenary-session-ii--rd-"><i class="fa fa-check"></i><b>8.1</b> Plenary Session II “의료기술및 R&amp;D 변화의최신동향”</a><ul>
<li class="chapter" data-level="8.1.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-1--------"><i class="fa fa-check"></i><b>8.1.1</b> 13:30 ~ 14:15 Lecture 1 :의료분야에서의 빅데이터 :임상연구 및 진료를 위한 애널리틱스의 활용</a></li>
<li class="chapter" data-level="8.1.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-2----"><i class="fa fa-check"></i><b>8.1.2</b> 14:15 ~ 15:00 Lecture 2 :합성 항체에서 합성 단백질로</a></li>
</ul></li>
<li class="chapter" data-level="8.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#parallel-session-i--chairperson--"><i class="fa fa-check"></i><b>8.2</b> Parallel Session I “의료분야에서의빅데이터” Chairperson :김태원(서울아산병원임상의학연구소장) [대강당]</a><ul>
<li class="chapter" data-level="8.2.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-1------alexander-turchin-harvard-university-brigham-and-womens-hospital-usa"><i class="fa fa-check"></i><b>8.2.1</b> Lecture 1 :전자의무기록에 기반한 임상 빅데이터 연구 Alexander Turchin (Harvard University, Brigham and Women’s Hospital, USA)</a></li>
<li class="chapter" data-level="8.2.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-2----tom-lawry-microsoft-corp.-usa"><i class="fa fa-check"></i><b>8.2.2</b> Lecture 2 : 의료분야에서의 빅데이터 분석 Tom Lawry (Microsoft Corp., USA)</a></li>
<li class="chapter" data-level="8.2.3" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-3-------"><i class="fa fa-check"></i><b>8.2.3</b> Lecture 3 :생물기작 기반 암 오믹스 데이터 분석 기법</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="9" data-path="acrep.html"><a href="acrep.html"><i class="fa fa-check"></i><b>9</b> ACREP</a><ul>
<li class="chapter" data-level="9.1" data-path="acrep.html"><a href="acrep.html#observational-study"><i class="fa fa-check"></i><b>9.1</b> Observational Study</a><ul>
<li class="chapter" data-level="9.1.1" data-path="acrep.html"><a href="acrep.html#contents"><i class="fa fa-check"></i><b>9.1.1</b> Contents</a></li>
</ul></li>
<li class="chapter" data-level="9.2" data-path="acrep.html"><a href="acrep.html#observational-study-pitfall-----"><i class="fa fa-check"></i><b>9.2</b> Observational Study의 Pitfall 및 이를 극복하기 위한 방법</a><ul>
<li class="chapter" data-level="9.2.1" data-path="acrep.html"><a href="acrep.html#experimental-study-yes"><i class="fa fa-check"></i><b>9.2.1</b> Experimental study? Yes</a></li>
<li class="chapter" data-level="9.2.2" data-path="acrep.html"><a href="acrep.html#experimental-study-no"><i class="fa fa-check"></i><b>9.2.2</b> Experimental study? No</a></li>
<li class="chapter" data-level="9.2.3" data-path="acrep.html"><a href="acrep.html#contents-1"><i class="fa fa-check"></i><b>9.2.3</b> Contents</a></li>
<li class="chapter" data-level="9.2.4" data-path="acrep.html"><a href="acrep.html#conclusion"><i class="fa fa-check"></i><b>9.2.4</b> Conclusion</a></li>
</ul></li>
<li class="chapter" data-level="9.3" data-path="acrep.html"><a href="acrep.html#diagnostic-test-biomarker-study"><i class="fa fa-check"></i><b>9.3</b> Diagnostic test &amp; Biomarker Study</a><ul>
<li class="chapter" data-level="9.3.1" data-path="acrep.html"><a href="acrep.html#contents---diagnostic-test"><i class="fa fa-check"></i><b>9.3.1</b> Contents - Diagnostic test</a></li>
<li class="chapter" data-level="9.3.2" data-path="acrep.html"><a href="acrep.html#contents---biomarker"><i class="fa fa-check"></i><b>9.3.2</b> Contents - Biomarker</a></li>
</ul></li>
<li class="chapter" data-level="9.4" data-path="acrep.html"><a href="acrep.html#----"><i class="fa fa-check"></i><b>9.4</b> 2차 자료원을 이용한 역학 연구군</a></li>
<li class="chapter" data-level="9.5" data-path="acrep.html"><a href="acrep.html#----clinical-prediction-model-individual-riskoutcome-probability--"><i class="fa fa-check"></i><b>9.5</b> 대규모 이차 자료원을 이용한 clinical prediction model : individual risk/outcome probability 예측 분석법</a></li>
<li class="chapter" data-level="9.6" data-path="acrep.html"><a href="acrep.html#web-r.org"><i class="fa fa-check"></i><b>9.6</b> Web-r.org</a><ul>
<li class="chapter" data-level="9.6.1" data-path="acrep.html"><a href="acrep.html#contents-2"><i class="fa fa-check"></i><b>9.6.1</b> Contents</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="10" data-path="prism-2016.html"><a href="prism-2016.html"><i class="fa fa-check"></i><b>10</b> Prism 2016</a><ul>
<li class="chapter" data-level="10.1" data-path="prism-2016.html"><a href="prism-2016.html#morning-session"><i class="fa fa-check"></i><b>10.1</b> Morning Session</a><ul>
<li class="chapter" data-level="10.1.1" data-path="prism-2016.html"><a href="prism-2016.html#lim-covariate-model"><i class="fa fa-check"></i><b>10.1.1</b> Lim Covariate model</a></li>
<li class="chapter" data-level="10.1.2" data-path="prism-2016.html"><a href="prism-2016.html#fda---lee"><i class="fa fa-check"></i><b>10.1.2</b> FDA - Lee</a></li>
<li class="chapter" data-level="10.1.3" data-path="prism-2016.html"><a href="prism-2016.html#pfizer"><i class="fa fa-check"></i><b>10.1.3</b> Pfizer</a></li>
</ul></li>
<li class="chapter" data-level="10.2" data-path="prism-2016.html"><a href="prism-2016.html#afternoon-session"><i class="fa fa-check"></i><b>10.2</b> Afternoon Session</a><ul>
<li class="chapter" data-level="10.2.1" data-path="prism-2016.html"><a href="prism-2016.html#kim"><i class="fa fa-check"></i><b>10.2.1</b> Kim</a></li>
<li class="chapter" data-level="10.2.2" data-path="prism-2016.html"><a href="prism-2016.html#strategic-application-of-pm-in-global-drug-development-experience-from-hanmi"><i class="fa fa-check"></i><b>10.2.2</b> Strategic application of PM in global drug development: Experience from Hanmi</a></li>
<li class="chapter" data-level="10.2.3" data-path="prism-2016.html"><a href="prism-2016.html#mbdd"><i class="fa fa-check"></i><b>10.2.3</b> MBDD</a></li>
<li class="chapter" data-level="10.2.4" data-path="prism-2016.html"><a href="prism-2016.html#pharmacometric-information-in-drug-label"><i class="fa fa-check"></i><b>10.2.4</b> Pharmacometric information in drug label</a></li>
<li class="chapter" data-level="10.2.5" data-path="prism-2016.html"><a href="prism-2016.html#pharmacometrics-in-dose-optimization"><i class="fa fa-check"></i><b>10.2.5</b> Pharmacometrics in Dose Optimization</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="11" data-path="MFDS.html"><a href="MFDS.html"><i class="fa fa-check"></i><b>11</b> MFDS-Asan Joint Symposium on Rare Diseases 2016</a><ul>
<li class="chapter" data-level="11.1" data-path="MFDS.html"><a href="MFDS.html#session-1-rare-diseases-in-korea-status-research-experiences"><i class="fa fa-check"></i><b>11.1</b> Session 1 Rare diseases in Korea : Status &amp; Research experiences</a><ul>
<li class="chapter" data-level="11.1.1" data-path="MFDS.html"><a href="MFDS.html#national-support-for-rare-disease-current-status-and-future-prospects"><i class="fa fa-check"></i><b>11.1.1</b> National support for rare disease : Current status and future prospects</a></li>
<li class="chapter" data-level="11.1.2" data-path="MFDS.html"><a href="MFDS.html#translational-research-for-drug-development-historical-perspective"><i class="fa fa-check"></i><b>11.1.2</b> Translational research for drug development : Historical perspective</a></li>
</ul></li>
<li class="chapter" data-level="11.2" data-path="MFDS.html"><a href="MFDS.html#session-2-global-regulatory-experiences-in-orphan-drug-development"><i class="fa fa-check"></i><b>11.2</b> Session 2 Global regulatory experiences in orphan drug development</a><ul>
<li class="chapter" data-level="11.2.1" data-path="MFDS.html"><a href="MFDS.html#considerations-for-drug-development-for-rare-diseases-cases-of-inborn-errors-of-metabolism"><i class="fa fa-check"></i><b>11.2.1</b> Considerations for drug development for rare diseases : Cases of inborn errors of metabolism</a></li>
<li class="chapter" data-level="11.2.2" data-path="MFDS.html"><a href="MFDS.html#role-of-pharmacometrics-in-the-development-of-orphan-drugs"><i class="fa fa-check"></i><b>11.2.2</b> Role of pharmacometrics in the development of orphan drugs</a></li>
</ul></li>
<li class="chapter" data-level="11.3" data-path="MFDS.html"><a href="MFDS.html#session-3-lessons-and-learned-rd-for-rare-disease"><i class="fa fa-check"></i><b>11.3</b> Session 3 Lessons and learned : R&amp;D for rare disease</a><ul>
<li class="chapter" data-level="11.3.1" data-path="MFDS.html"><a href="MFDS.html#lessons-from-an-orphan-drug-development-i"><i class="fa fa-check"></i><b>11.3.1</b> Lessons from an orphan drug development (I)</a></li>
<li class="chapter" data-level="11.3.2" data-path="MFDS.html"><a href="MFDS.html#lessons-from-an-orphan-drug-development-ii"><i class="fa fa-check"></i><b>11.3.2</b> Lessons from an orphan drug development (II)</a></li>
<li class="chapter" data-level="11.3.3" data-path="MFDS.html"><a href="MFDS.html#case-studies-on-inflammatory-bowel-disease-asan-medical-center"><i class="fa fa-check"></i><b>11.3.3</b> Case studies on inflammatory bowel disease Asan Medical Center</a></li>
<li class="chapter" data-level="11.3.4" data-path="MFDS.html"><a href="MFDS.html#case-studies-on-drug-targets-in-rare-ultra-rare-genetic-disorders"><i class="fa fa-check"></i><b>11.3.4</b> Case studies on drug targets in rare &amp; ultra-rare genetic disorders</a></li>
</ul></li>
<li class="chapter" data-level="11.4" data-path="MFDS.html"><a href="MFDS.html#session-4-asan-initia-tives-for-rare-disease"><i class="fa fa-check"></i><b>11.4</b> Session 4 Asan initia tives for rare disease</a><ul>
<li class="chapter" data-level="11.4.1" data-path="MFDS.html"><a href="MFDS.html#leverage-big-data-to-better-understand-rare-disease-states-and-patient-needs-rare-disease-registry-research-experience"><i class="fa fa-check"></i><b>11.4.1</b> Leverage big data to better understand rare disease states and patient needs (rare disease registry &amp; research experience)</a></li>
<li class="chapter" data-level="11.4.2" data-path="MFDS.html"><a href="MFDS.html#align-commercial-and-development-team-to-forecast-success-through-prism"><i class="fa fa-check"></i><b>11.4.2</b> Align commercial and development team to forecast success through “PRISM”</a></li>
<li class="chapter" data-level="11.4.3" data-path="MFDS.html"><a href="MFDS.html#knowledge-and-perceptions-of-clinical-research-of-patients-suffering-from-rare-diseases"><i class="fa fa-check"></i><b>11.4.3</b> Knowledge and perceptions of clinical research of patients suffering from rare diseases</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="12" data-path="toxicology-2016.html"><a href="toxicology-2016.html"><i class="fa fa-check"></i><b>12</b> Toxicology 2016</a><ul>
<li class="chapter" data-level="12.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#key-links"><i class="fa fa-check"></i><b>12.1</b> Key links</a></li>
<li class="chapter" data-level="12.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#session-i-2016-08-22"><i class="fa fa-check"></i><b>12.2</b> Session I 2016-08-22</a><ul>
<li class="chapter" data-level="12.2.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#---"><i class="fa fa-check"></i><b>12.2.1</b> 독성학 개론 및 발현기전 !!!!</a></li>
<li class="chapter" data-level="12.2.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.2.2"><i class="fa fa-check"></i><b>12.2.2</b> 면역독성 !</a></li>
<li class="chapter" data-level="12.2.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#-"><i class="fa fa-check"></i><b>12.2.3</b> 독성시험과 통계 !!</a></li>
<li class="chapter" data-level="12.2.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.2.4"><i class="fa fa-check"></i><b>12.2.4</b> 독성병리 !!</a></li>
<li class="chapter" data-level="12.2.5" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.2.5</b> 비임상시험결과의 임상시험 연계 !!!!</a></li>
</ul></li>
<li class="chapter" data-level="12.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#session-ii-2016-08-23"><i class="fa fa-check"></i><b>12.3</b> Session II 2016-08-23</a><ul>
<li class="chapter" data-level="12.3.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#---"><i class="fa fa-check"></i><b>12.3.1</b> 오믹스 기반을 이용한 독성평가 !</a></li>
<li class="chapter" data-level="12.3.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.2</b> 독성동태 및 대사 !!!</a></li>
<li class="chapter" data-level="12.3.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.3</b> 유전독성 및 발암성 !!</a></li>
<li class="chapter" data-level="12.3.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.3.4"><i class="fa fa-check"></i><b>12.3.4</b> 신경독성 !</a></li>
<li class="chapter" data-level="12.3.5" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.5</b> 식품의 위해도 평가 !</a></li>
<li class="chapter" data-level="12.3.6" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.3.6"><i class="fa fa-check"></i><b>12.3.6</b> 생식발생독성 !</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="13" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><i class="fa fa-check"></i><b>13</b> 2016년 신약임상개발 전문가 과정 “Clinical Research Science Expert Course for Cutting-edge Drug Development”</a><ul>
<li class="chapter" data-level="13.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#drug-discovery-and-preclinical-candidate-selection"><i class="fa fa-check"></i><b>13.1</b> Drug discovery and preclinical candidate selection</a><ul>
<li class="chapter" data-level="13.1.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#-1st"><i class="fa fa-check"></i><b>13.1.1</b> 김재은 (1ST)</a></li>
</ul></li>
<li class="chapter" data-level="13.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#preclinical-development-and-ind-gono-go-decision-using-case-studies"><i class="fa fa-check"></i><b>13.2</b> Preclinical development and IND go/no-go decision (using case studies)</a></li>
<li class="chapter" data-level="13.3" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#global-drug-development-and-interaction-with-regulatory-agencies-fda-emea-using-case-studies"><i class="fa fa-check"></i><b>13.3</b> Global drug development and interaction with regulatory agencies (FDA, EMEA) (using case studies)</a></li>
<li class="chapter" data-level="13.4" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#clinical-pharmacology"><i class="fa fa-check"></i><b>13.4</b> Clinical Pharmacology</a></li>
<li class="chapter" data-level="13.5" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#the-actual-development-and-operation-of-pharmacovigillance-system-in-korean-pharmaceutical-companies"><i class="fa fa-check"></i><b>13.5</b> The actual development and operation of Pharmacovigillance system in Korean pharmaceutical companies</a><ul>
<li class="chapter" data-level="13.5.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#experience-of-sop-development-pv-training-sharing-pv-audit-finding"><i class="fa fa-check"></i><b>13.5.1</b> Experience of SOP development &amp; PV training/ Sharing PV audit finding</a></li>
<li class="chapter" data-level="13.5.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#establishment-and-application-of-safety-database-system"><i class="fa fa-check"></i><b>13.5.2</b> Establishment and Application of Safety Database System:</a></li>
</ul></li>
<li class="chapter" data-level="13.6" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#open-innovation-in-drug-development"><i class="fa fa-check"></i><b>13.6</b> Open innovation in drug development</a></li>
<li class="chapter" data-level="13.7" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#clinical-development-strategy-and-plan-workshop"><i class="fa fa-check"></i><b>13.7</b> Clinical development strategy and plan workshop</a><ul>
<li class="chapter" data-level="13.7.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#course-intro---understanding-tpp-and-hcv"><i class="fa fa-check"></i><b>13.7.1</b> Course intro - Understanding TPP and HCV</a></li>
<li class="chapter" data-level="13.7.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#candidate-selection-through-poc"><i class="fa fa-check"></i><b>13.7.2</b> Candidate selection through PoC</a></li>
<li class="chapter" data-level="13.7.3" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#late-phase-development-commercialization"><i class="fa fa-check"></i><b>13.7.3</b> Late phase Development &amp; Commercialization</a></li>
<li class="chapter" data-level="13.7.4" data-path="acrep.html"><a href="acrep.html#----"><i class="fa fa-check"></i><b>13.7.4</b> 국내 사례 소개 및 질의/응답</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="14" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html"><i class="fa fa-check"></i><b>14</b> The 2nd A3 Pharmacometrics Symposium</a><ul>
<li class="chapter" data-level="14.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#young-scientist-session"><i class="fa fa-check"></i><b>14.1</b> Young Scientist Session</a><ul>
<li class="chapter" data-level="14.1.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#modeling-of-mycoplasma-tuberculosis-biomarkders-for-cure"><i class="fa fa-check"></i><b>14.1.1</b> Modeling of mycoplasma tuberculosis biomarkders for cure</a></li>
<li class="chapter" data-level="14.1.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#integrative-pkpd-modling-and-simulation-of-amenamevir-for-treatment-of-recurrent-genital-herpes"><i class="fa fa-check"></i><b>14.1.2</b> Integrative PKPD modling and simulation of Amenamevir for treatment of recurrent genital herpes</a></li>
<li class="chapter" data-level="14.1.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#model-based-meta-analysis-to-quantify-and-compare-the-efficacy-of-non-hormonal-drugs-on-menopausal-hot-flashes"><i class="fa fa-check"></i><b>14.1.3</b> Model Based Meta-Analysis to quantify and compare the efficacy of non-hormonal drugs on menopausal Hot flashes</a></li>
<li class="chapter" data-level="14.1.4" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#dosing-optimization-in-obesity-using-pharmacometrics-approach-population-pk-and-pd-of-meropenem-in-non-obese-obese-and-mobidly-obese-patients"><i class="fa fa-check"></i><b>14.1.4</b> Dosing optimization in obesity using pharmacometrics approach: population PK and PD of meropenem in non-obese, obese and mobidly obese patients</a></li>
</ul></li>
<li class="chapter" data-level="14.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#application-session"><i class="fa fa-check"></i><b>14.2</b> Application Session</a><ul>
<li class="chapter" data-level="14.2.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#the-application-of-pharmacometrics-in-individual-therapy-in-china"><i class="fa fa-check"></i><b>14.2.1</b> The application of pharmacometrics in individual therapy in China</a></li>
<li class="chapter" data-level="14.2.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#pd-model-fo-bayesian-prediction-of-myelosuppression-rpofiles-based-on-routine-clinical-data-after-gemcitabine-and-carboplatin-treatment"><i class="fa fa-check"></i><b>14.2.2</b> PD model fo Bayesian Prediction of myelosuppression rpofiles based on routine clinical data after gemcitabine and carboplatin treatment</a></li>
<li class="chapter" data-level="14.2.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#modeling-and-validating-chronic-pharmacological-manupulation-of-circadian-rhythms"><i class="fa fa-check"></i><b>14.2.3</b> Modeling and validating chronic pharmacological manupulation of circadian rhythms</a></li>
<li class="chapter" data-level="14.2.4" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#application-of-pkpd-modeling-and-simulation-in-antiviral-drug-development"><i class="fa fa-check"></i><b>14.2.4</b> Application of PK/PD modeling and simulation in antiviral drug development</a></li>
<li class="chapter" data-level="14.2.5" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#pharmacometrics-in-clinical-practice-pop-pk-analysis-of-febuxostat-in-patients-with-severe-renal-impairment"><i class="fa fa-check"></i><b>14.2.5</b> pharmacometrics in clinical practice: pop PK analysis of febuxostat in patients with severe renal impairment</a></li>
</ul></li>
<li class="chapter" data-level="14.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#regulation"><i class="fa fa-check"></i><b>14.3</b> Regulation</a><ul>
<li class="chapter" data-level="14.3.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#japan"><i class="fa fa-check"></i><b>14.3.1</b> Japan</a></li>
<li class="chapter" data-level="14.3.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#korea"><i class="fa fa-check"></i><b>14.3.2</b> Korea</a></li>
<li class="chapter" data-level="14.3.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#ema-regulations-on-meling-issues"><i class="fa fa-check"></i><b>14.3.3</b> EMA regulations on meling issues</a></li>
<li class="chapter" data-level="14.3.4" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#recent-examples-of-impact-of-pharmacometrics-in-decision-making"><i class="fa fa-check"></i><b>14.3.4</b> Recent examples of impact of pharmacometrics in decision making</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="15" data-path="reference.html"><a href="reference.html"><i class="fa fa-check"></i><b>15</b> Reference</a></li>
<li class="divider"></li>
<li><a href="http://shanmdphd.github.io">Back to shanmdphd.github.io</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Conferences 2016</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="kscpt" class="section level1">
<h1><span class="header-section-number">Chapter 7</span> 2016 KSCPT</h1>
<div class="figure">
<img src="images/2016KSCPT.jpg" alt="Materials" />
<p class="caption">Materials</p>
</div>
<div id="opening-remark" class="section level2">
<h2><span class="header-section-number">7.1</span> Opening Remark</h2>
<ul>
<li>Yil-Seob Lee (president of KSCPT)</li>
</ul>
</div>
<div id="first-session" class="section level2">
<h2><span class="header-section-number">7.2</span> First Session</h2>
<ul>
<li>Chair : Deborah Chee(KoNECT)</li>
</ul>
<div id="precision-medicine-a-clinical-pharmacological-perspective" class="section level3">
<h3><span class="header-section-number">7.2.1</span> 13:20~14:00 Precision Medicine: A Clinical Pharmacological Perspective</h3>
<ul>
<li>Speaker: <a href="https://en.wikipedia.org/wiki/Munir_Pirmohamed">Munir Pirmohamed</a> (University of Liverpool, UK)</li>
<li>Fava beans - Favism G6PD deficiency - withrawal of antimalarials</li>
<li>2015 Obama Precision Medicine $215m / 2016 China $8b</li>
<li>Phenotypic definition(current standard) - Molecular definition (disease stratification) - Drug variability</li>
<li>Mandatory genomic testing - EMA SmPC</li>
<li>Pharmacogenomics Journal (2015) 1-10</li>
<li>Crizotinib vs CTx in advanced ALK+ lung cancer (NEJM 2013)</li>
<li>Novel trial design (Nature 2015)</li>
</ul>
<ol style="list-style-type: decimal">
<li>Umbrella trial (single tumor - multiple arm - multiple drugs)</li>
<li>Basket study</li>
</ol>
<ul>
<li>Support of humen genetic evidence for approved drug indication (Nature Genetics)</li>
<li>Sclerosteosis - skeletal overgrowth and syndactyly, AR , mutations in SOST gene - target sclerostin</li>
<li>anti-sclerostin Ab (ROMOSOZUMAB, BLOSOZUMAB) - bone density increase - mouse</li>
<li>New cardiovascular targets</li>
<li>PCSK9 - GOF-&gt;LDL-C increase &amp; CVD</li>
<li>ANGPTL4</li>
<li>HLA-genotype and carbamazepine-induced cutaneous ADR: systemic review (CPT,2012)</li>
<li>ITCH (Drug hypersensitivity)</li>
<li>Phase I, II - very strong association (Manhattan plot) - GWAS - ALK(germline polymorphism-&gt; T cell expansion)</li>
<li>SJS GWAS (Genin 2011) <a href="http://www.ncbi.nlm.nih.gov/pubmed/21801394" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/21801394</a></li>
<li>Skin, Liver</li>
<li>CBZ-induced hypersensitivity vs CBZ-tolerant patients</li>
<li>HLA-A*31:01(thirtyone o one)</li>
<li>HLA and ADR</li>
<li>The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. (2016) <a href="http://www.ncbi.nlm.nih.gov/pubmed/26478982" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/26478982</a></li>
<li>Somatic genomes -&gt; microbiome is also important</li>
<li>Digoxin and antibiotics (1981, NEJM) -&gt; (2013 Science) Cardiac drug inactivation by human gut bacteria</li>
<li>Microbiome and Cancer Immunotherapy - Snyder, Science Nov 2015</li>
<li>Two books introduced.</li>
</ul>
<ol style="list-style-type: decimal">
<li>Prescription for nhs</li>
<li>clinical pharma dynamic medical specialty</li>
</ol>
</div>
<div id="the-role-of-pharmacogenomics-in-drug-development-regulatory-review-and-clinical-practice" class="section level3">
<h3><span class="header-section-number">7.2.2</span> 14:00~14:30 The role of pharmacogenomics in drug development, regulatory review and clinical practice</h3>
<ul>
<li>Speaker: Shiew-Mei Huang (North Potomac, MD, USA)</li>
<li>CPIC (Clinical pharmacogenetics guidelines)</li>
<li>IFNL3(IL28B) HCV treatment Favorable response = 77% Asian (Genotype CC)</li>
<li>Paving the way for Personalized Medicine (Oct 2013)</li>
<li>Avacavir HLA-B*5701 (RCT) Utility of pharmacogenetic tests</li>
<li>Munir mentioned - CBZ &amp; HLA-B*1502</li>
<li>ASCO meeting - CTx vs Targeted therapy - Umbrella study</li>
<li>Drug labeling “FDA-approved test”</li>
<li>XALKORI - Crizotinib and ALK</li>
<li>CPT Feb 2016 - Precision Medicine , “Companion Diagnostics” Something unique to conduct , “Complementary diagnostics”</li>
<li>Eliglustat and CYP2D6 , Drug labeling</li>
<li>Center for Device</li>
<li>Integral to the future of personalized or precision medicine</li>
<li>NGS</li>
<li>PrecisionFDA initiative</li>
<li>23andMe - Drug response , Confidence</li>
<li>Cleared or approved FDA</li>
<li>CLIA-certified laboratory</li>
</ul>
<div id="my-question" class="section level4">
<h4><span class="header-section-number">7.2.2.1</span> My Question</h4>
<ul>
<li>One NGS - individual test to is there a review of all-in-one Test in progress?</li>
</ul>
</div>
</div>
<div id="the-liver-gut-microbiota-axis-modulates-inter-individual-variability-in-xenobiotic-disposition-and-toxicology" class="section level3">
<h3><span class="header-section-number">7.2.3</span> 14:30~15:00 The Liver-Gut Microbiota Axis Modulates Inter-Individual Variability in Xenobiotic Disposition and Toxicology</h3>
<ul>
<li>Speaker: Eric Chun Yong Chan (National University of Singapore)</li>
<li>Liver - major organ for disposition and detoxification</li>
<li>60% (explanble) vs 40% (how about this?) - superorganism</li>
<li>400 different species (~1.5kg)</li>
<li>Haiser (2012, Science) Gut microbe - drug, host interaction</li>
<li>TOC: 1 DMD paper , 2 in-house project</li>
<li>DMD - reduction, hydrolysis</li>
<li>absorption - simvastatin - poor responder, average, good 10% 80% 10%
<ul>
<li>OATP1B1 in liver and intestine</li>
<li>Possibility of competition between simvastatin and bile acids for hepatic uptake by transporter</li>
<li>antibiotics - nitro-reduction by gut microbiota inhibition</li>
<li>Therapeutic fficacy - DDI</li>
</ul></li>
<li>PCA analysis PNAS 2009 - significant differences in concentration</li>
<li>PNAS 2009 inverse corr - p-cresol &lt;-&gt; AAP</li>
<li>2nd part - Tacrine - first drug approved for AD. Toxicological manifestation - increased AST/ALT</li>
<li>Interindividual variability. why?</li>
<li>Tacrine metabolism - hydroxylation / glucuronide</li>
<li>mitochondrial toxicity and hypoxia-reoxygenation</li>
<li>part I~V</li>
<li>Tacrine-induced transaminitis</li>
<li>EXT - CMax,AUC high why? - phase II metabolite?</li>
<li>host gene - mRNA</li>
<li>GC/TO</li>
<li>PCA analysis principal component analysis</li>
<li>NORMAL Lactobacillus</li>
<li>EXT Bacteriode Blautia</li>
<li>Metagenome level</li>
<li>Liver - Tacrine-&gt; TacrineNGlucuronide</li>
</ul>
</div>
</div>
<div id="second-session" class="section level2">
<h2><span class="header-section-number">7.3</span> Second Session</h2>
<ul>
<li>Chair : Yong-Bok Lee(Chonnam National University)</li>
</ul>
<div id="the-role-of-stem-cells-in-discovery-and-validation-of-pharmacogenomic-markers" class="section level3">
<h3><span class="header-section-number">7.3.1</span> 15:20~15:50 The role of stem cells in discovery and validation of pharmacogenomic markers</h3>
<ul>
<li>Speaker : Eileen Dolan (The University of Chicago, USA)</li>
<li>Ototoxicity, CTx Toxicity - hearing loss, peripheral neuropathy</li>
<li>dose-limiting toxicity - platinum, taxanes, vinca, epothilones, bortezomib</li>
<li>numbness, tingling, burning/stabbing pain</li>
<li>partially , can be permanent</li>
<li>Duloxetine - SNRI - CIPN</li>
<li>pharmacogenomic studies - optimal model - testicular cancer -</li>
<li>platinating agents</li>
<li>CIPN - &gt;300mg/m2, dorsal root g. cell apoptosis, affects large neurons, axonal projections</li>
<li>CTCAE of CIPN, patient-reported measures preferred (CIPN EORTC-CPIN20)</li>
<li>PCA analysis</li>
<li>age, smoking</li>
<li>GWAS - CIPN6 -&gt; CAMTA1, RGS, WDR1, MAPK9, COA1, ILR2A</li>
<li>Polygenic architecture</li>
<li>PIPN : ECOG: rs3125923</li>
<li>Stem cells - problems - identifying, priortizing</li>
<li>cell-based PD analysis</li>
<li>iPSC technology in PGx, CRISPR</li>
<li>Neuronal measurements - total outgrowth processes, process length, branches, cell body area</li>
<li>C, P, 5FU, Bortezomib, Vinc, Thalidomide</li>
<li>inhibition of neurite outgrowth</li>
<li>VIN - GWAS 2000 patients</li>
<li>CEP72 - microtubules assembly, TT allele - susceptible -&gt; lower CEP72 mRNA expression</li>
<li>knockdown of CEP72 in iPCSC -&gt; enhancing sensitivity to vincristine</li>
</ul>
<div id="questions---neurite-outgrowth" class="section level4">
<h4><span class="header-section-number">7.3.1.1</span> Questions - neurite outgrowth</h4>
<ul>
<li>Neurons- mature enough?</li>
</ul>
</div>
</div>
<div id="pharmacogenomics-and-epigenomics" class="section level3">
<h3><span class="header-section-number">7.3.2</span> 15:50~16:20 Pharmacogenomics and Epigenomics</h3>
<ul>
<li>Speaker: Matthias Schwab (IKP Stuttgart, Germany)</li>
<li>Prognostic predictors</li>
<li>Genetic make-up</li>
<li>135 FDA-approved drugs with labeled pharmacogenomic information (2015-05-20)</li>
<li>top 30 drugs with pharmacogenetic risk (w/ or w/o high-risk diplotype for gene)</li>
<li>Genomics, proteomics metabolomics, microbiomics</li>
<li>Genome Medicine 2016 (Auffray, Schwab)</li>
<li>NEJM</li>
<li>Cocktail approach - a single dose PK study - old fashion clinical pharmacology approach? -</li>
<li>Metoprolol and Torsemide PK - heretability</li>
<li>Koryza Genet Med 2016 - comprehensive analysis - ESP project (n=6500) and 1000 genomes project</li>
<li>PNAS 2005 Fraga - Epigenomics and DNA methylation</li>
<li>miRNA, methylation, histone modification(acetylation)</li>
<li>CPT 2016, Fisel, Schaeffeler, Schwab - DNA methylation and its impact on disease pathophysioloy and drug therapy</li>
<li>Heatmap - ADME genes - SLC transporters</li>
</ul>
<div id="my-quesion" class="section level4">
<h4><span class="header-section-number">7.3.2.1</span> My Quesion</h4>
<ul>
<li>Can we develop therapeutics which target locus of epigenetic (Decitabine)- Renal cancer cell - treatment of decitabine - demethylating agents (Specificity?)</li>
<li>Epigenomics</li>
</ul>
</div>
</div>
<div id="emerging-roles-of-human-cyp1b1-in-cancer-growth-and-metastasis" class="section level3">
<h3><span class="header-section-number">7.3.3</span> 16:20~16:50 Emerging roles of human CYP1B1 in cancer growth and metastasis</h3>
<ul>
<li>Speaker: Young-Jin Chun (Chung-Ang University, KOREA)</li>
<li>P450 (CYP1B1)</li>
<li>Estrogen metabolism : E2-&gt;4-OHE2(endogenous mutagen)</li>
<li>ZYC300 cancer vaccine - CYP1B1 DNA Vaccine</li>
<li>Immunity to CYP1B1 -&gt; Clinical benefit</li>
<li>과발현시 - PCNA increased</li>
<li>TMS - specific human CYP1B1 - DMBA-&gt;PPCNA increased, DMBA+TMS-&gt;PBNA back to normal</li>
<li>CYP1B1 -&gt; EMT (ECADHERIN, ZEB1, Vimentin, twist1 ) FUNCTIONAL STUDY , Can we transmembrane migration - cancer progression</li>
<li>SP1 Transctiption factors - Mithramycin A(binding inhibittor) DMBA에의해 증가한 에스피1등이 mitA를 억제.</li>
<li>이러한 결과들을 통해서 SP1이 암 증식 chip assay</li>
<li>4OHE는 EMT 촉진된다.</li>
<li>억제 - Mithramycin A</li>
<li>촉진 - DMBA, CYP1B1, SP1, 4OHE</li>
<li>Matrigel, migration -&gt; migration, invasion</li>
</ul>
<div id="section" class="section level4">
<h4><span class="header-section-number">7.3.3.1</span> </h4>
<p>1B1에 의해 대사되는 irinotecan - 알수가 없다. Tumor 조직을 갖고 enzyme activity 측정전에. active metabolism 2D6는 steroid</p>
</div>
</div>
<div id="omics-for-precision-medicine-clinical-implementation-in-oncology" class="section level3">
<h3><span class="header-section-number">7.3.4</span> 16:50~17:20 omics for precision Medicine : Clinical Implementation in oncology</h3>
<ul>
<li>Speaker: Kyu-pyo Kim (University of Ulsan College of Medicine, KOREA)</li>
<li>effects are not immediate / severe adverse effects / narrow therapeutic window</li>
<li>UGT1A1 genotypes - different enzyme activities , Irinotecan</li>
<li>Irinotecan -&gt; practical decision making - not reached.</li>
<li>genotype information - strong enough?</li>
<li>neutropenia, diarrhea</li>
<li>mutations are abundant - mutational loading (high- melanoma, lung sq cel carcinoma)</li>
<li>Point mutations, copy # variation -&gt; omics + NGS -&gt; clinical interpretation -&gt; clinical decision making</li>
<li>Ca Cancer J Clin 2016 - 1 month TIME IS IMPORTANT FOR PATIENTS.</li>
<li>Issues : Forces or hurdles - COSTS - volume of patients/turnaround time/Central testing/Quality control</li>
<li>NCI-Match - somatic mutation - Oncomine Comprehensive Assay Gene List - How to report???</li>
<li>KRAS A146 mutation in CRC -&gt; CTX guideline - clinical trial</li>
<li>CPCM - KCSG 11th methodology -</li>
<li>Transition : from research to practice - CLIA (23andMe)</li>
<li>NGS 임상검사실 인증제도 추진중임.</li>
<li>Summary - abundance of information is helpting us</li>
<li>there are many hurdles</li>
<li>multi-disciplinary efforts are needed.</li>
</ul>

</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="-fda-.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="translation-and-convergence-for-future-medicine.html" class="navigation navigation-next " aria-label="Next page""><i class="fa fa-angle-right"></i></a>

<script src="libs/gitbook/js/app.min.js"></script>
<script src="libs/gitbook/js/lunr.js"></script>
<script src="libs/gitbook/js/plugin-search.js"></script>
<script src="libs/gitbook/js/plugin-sharing.js"></script>
<script src="libs/gitbook/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook/js/plugin-bookdown.js"></script>
<script src="libs/gitbook/js/jquery.highlight.js"></script>
<script>
require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"facebook": true,
"twitter": true,
"google": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/shanmdphd/shanmdphd.github.io/edit/master/_ConferencesSource/2016-06-14-2016-KSCPT.rmd",
"text": "Edit"
},
"download": ["bookdown.pdf", "bookdown.epub", "bookdown.mobi"],
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    if (location.protocol !== "file:" && /^https?:/.test(script.src))
      script.src  = script.src.replace(/^https?:/, '');
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
